Replies to post #644471 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

While the size of the arms in the DCVax-l + poly-iclc trial were small, the effect against both unmethylated and methylated GBM were astounding. Remember, unmethylated make up 60% of the GBM population across the globe. So the DCVax-l combo with poly-iclc is helpful to show DCVax-l comprehensive impact.

In that small trial, the DCVax-l + Poly-ICLC arm showed:

100% unmethylated GBM (idh wildtype) patients lived over two years. (n = 4)

100% methylated GBM (idh wildtype) patient lived over four years. (n = 1)

100% Grade III brain tumor patients are still alive. (Between six and ten years). (n = 4)

https://www.researchsquare.com/article/rs-3287211/v1

Yes, the trial did not power itself for survival, but the results in that arm are nonetheless stunning.